Open AccessShort-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor–Positive Breast Cancers
Author(s) -
Andrea M. Pesch,
Nicole Hirsh,
Benjamin C. Chandler,
Anna R. Michmerhuizen,
Cassandra L. Ritter,
Marlie P. Androsiglio,
Kari Wilder-Romans,
Meilan Liu,
Christina L. Gersch,
José M. Larios,
Lori J. Pierce,
James M. Rae,
Corey Speers
Publication year - 2020
Publication title -
clinical cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.427
H-Index - 324
eISSN - 1557-3265
pISSN - 1078-0432
DOI - 10.1158/1078-0432.ccr-20-2269
Subject(s) - palbociclib , cancer research , clonogenic assay , rad51 , breast cancer , medicine , estrogen receptor , radiation therapy , cancer , dna damage , dna repair , oncology , biology , cell culture , metastatic breast cancer , dna , genetics
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have improved progression-free survival for metastatic, estrogen receptor-positive (ER + ) breast cancers, but their role in the nonmetastatic setting remains unclear. We sought to understand the effects of CDK4/6 inhibition (CDK4/6i) and radiotherapy in multiple preclinical breast cancer models.